Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Robert J. Soiffer, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Chair, Executive Committee for Clinical Programs
  • Vice Chair, Department of Medical Oncology
  • Chief, Division of Hematologic Malignancies
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Chronic lymphocytic leukemia
  • Leukemias
  • Lymphoma
  • Stem cell/bone marrow transplantation

Diseases Treated

  • Allogeneic Stem Cell Transplant

Contact Information

  • Appointments617-632-5138 (new)
    617-632-6256 (follow-up)
  • Office Phone Number617-632-6256
  • Fax617-632-5168

Bio

Dr. Soiffer graduated from New York University School of Medicine in 1983, and trained in internal medicine at Brigham and Women's Hospital, where he also was chief medical resident. He joined DFCI in 1988, after completing a medical oncology fellowship. He is currently chief of the Division of Hematologic Malignancies and codirector of the Adult Stem Cell Transplantation Program. Dr. Soiffer is chairman of the Center for International Blood and Marrow Transplant Research advisory committee and has served as vice president (2006), president (2007), and immediate past president (2008) of the American Society of Blood and Marrow Transplantation.

Board Certification:

  • Internal Medicine, 1986
  • Medical Oncology, 1989

Fellowship:

  • Dana-Farber Cancer Institute, Hematology & Oncology

Residency:

  • Brigham and Women's Hospital, Chief Medical Resident
  • Brigham and Women's Hospital, Internal Medicine
  • West Roxbury Veterans Administration Medical Center, Chief Medical Resident

Medical School:

  • New York University

Recent Awards:

  • Baruj Benacerraf Fellow, DFCI 1997
  • Scholar for Clinical Research, Leukemia Society of America 1999
  • Brian O'Dell Memorial Research Award 2001
  • Lee M. Nadler "Extra Mile" Award, DFCI 2004

Research

Immunomodulation and Hematopoietic Stem Cell Transplantation

The focus of our research for the past decade has been the development of treatment strategies to modulate the immune system of patients with cancer. These efforts are based on studies of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies. Although allogeneic transplantation can cure a proportion of these individuals, success is limited by transplant-related complications such as graft-versus-host disease (GVHD). It has long been recognized that T lymphocytes from the donor marrow play a pivotal role in the pathogenesis of GVHD. In patients undergoing HSCT, depleting donor marrow T cells with an antibody to a T cell surface structure results in a dramatic decrease in the incidence of GVHD. This approach also eliminates the need for immune-suppressive medications. These agents can be toxic, causing organ damage and increasing susceptibility to infection. Recently we have explored strategies to selectively infuse CD8+ depleted lymphocytes in hopes of prompting graft-versus-leukemia (GVL) activity without producing GVHD. We validated this strategy in a randomized trial of CD8-depleted donor lymphocyte infusions after T cell-depleted allotransplantation, and are now conducting further trials on CD8 depletion. While T cell depletion reduces GVHD, its effect on immune reactivity may lead to an increased risk of relapse of certain leukemias after transplantation. Preserving and restoring this GVL activity without compromising safety is a major thrust of our clinical and laboratory research. Working within the Cell Manipulation Core Facility, we have begun to identify specific T cell populations that may play a critical role in mediating antileukemia activity. We are exploring the role of regulatory T cells (Tregs) in the development of GVHD and GVL reactions, and have initiated a clinical trial to augment GVL reactivity using an antibody to CTLA4Ig, a molecule that controls immune reactions.We are also investigating vaccination strategies for preventing relapse in allogeneic transplant patients. Previously, in collaboration with Dr. Glenn Dranoff, we found that vaccination with irradiated autologous tumor cells - genetically engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF) - induced histologic, cellular, and humoral evidence of autologous antitumor immunity in nontransplant patients. We are combining vaccine approaches with the administration of allogeneic donor stem cells in hopes of inducing a synergistic antileukemia effect.

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 Aug 26.
View in: PubMed

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021 07 22; 138(3):273-282.
View in: PubMed

Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leuk Lymphoma. 2021 Jun 11; 1-8.
View in: PubMed

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 Jun 10; 137(23):3212-3217.
View in: PubMed

Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 May; 56(5):1217.
View in: PubMed

Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis. Transpl Infect Dis. 2021 Apr 18; e13619.
View in: PubMed

HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood. 2021 Apr 13.
View in: PubMed

Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223.
View in: PubMed

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transplant Cell Ther. 2021 06; 27(6):483.e1-483.e6.
View in: PubMed

Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 06; 27(6):479.e1-479.e7.
View in: PubMed

Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease. Transplant Cell Ther. 2021 05; 27(5):433.e1-433.e8.
View in: PubMed

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871.
View in: PubMed

COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. Br J Haematol. 2021 04; 193(1):43-51.
View in: PubMed

Primum non nocere: allo-HSCT for AML in CR1. Blood. 2021 01 28; 137(4):438-439.
View in: PubMed

Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364.
View in: PubMed

Randomized Study of enterade® to Reduce Diarrhea in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. Asian Pac J Cancer Prev. 2021 Jan 01; 22(1):301-304.
View in: PubMed

Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer. 2021 Mar 15; 127(6):875-883.
View in: PubMed

Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175.
View in: PubMed

Topical sirolimus for management of refractory oral chronic graft-versus-host disease. Oral Dis. 2021 Sep; 27(6):1451-1454.
View in: PubMed

Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561).
View in: PubMed

Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 05; 56(5):1006-1012.
View in: PubMed

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123.
View in: PubMed

Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest. 2020 09 01; 130(9):4624-4636.
View in: PubMed

Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute. Blood Adv. 2020 07 14; 4(13):3205-3208.
View in: PubMed

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
View in: PubMed

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191.
View in: PubMed

BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv. 2020 05 12; 4(9):1881-1893.
View in: PubMed

Defibrotide formulations contain (1?3)-ß-D-glucan that could influence clinical diagnostic testing. Bone Marrow Transplant. 2020 10; 55(10):2045-2046.
View in: PubMed

Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. Br J Haematol. 2020 08; 190(4):583-587.
View in: PubMed

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood. 2020 01 02; 135(1):28-40.
View in: PubMed

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission. Blood. 2019 Nov 13; 134(Supplement_1):48.
View in: PubMed

Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):529-539.
View in: PubMed

A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810.
View in: PubMed

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020 03; 55(3):485-495.
View in: PubMed

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561.
View in: PubMed

A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020 05; 26(5):835-844.
View in: PubMed

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2019 12; 25(12):2383-2387.
View in: PubMed

Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019 08; 54(Suppl 2):798-802.
View in: PubMed

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019 07 23; 3(14):2199-2204.
View in: PubMed

Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). Biol Blood Marrow Transplant. 2019 11; 25(11):2143-2151.
View in: PubMed

Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019 07 25; 134(4):374-382.
View in: PubMed

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
View in: PubMed

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):984-994.
View in: PubMed

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):969-979.
View in: PubMed

Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies. J Am Geriatr Soc. 2019 05; 67(5):889-897.
View in: PubMed

Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease. Am J Transplant. 2019 06; 19(6):1820-1830.
View in: PubMed

Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation. Respir Res. 2019 Jan 21; 20(1):15.
View in: PubMed

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019 01; 7(1):100-112.
View in: PubMed

Evaluating the adverse effects of melphalan formulations. J Oncol Pharm Pract. 2019 Oct; 25(7):1631-1637.
View in: PubMed

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2019 01 03; 133(1):94-99.
View in: PubMed

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):137-144.
View in: PubMed

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant. 2018 11; 24(11):2216-2223.
View in: PubMed

Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. Biol Blood Marrow Transplant. 2018 10; 24(10):2164-2165.
View in: PubMed

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv. 2018 06 12; 2(11):1180-1186.
View in: PubMed

Can IL-15 superagonist ALTer GVL? Blood. 2018 06 07; 131(23):2511-2512.
View in: PubMed

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. Pediatr Blood Cancer. 2018 10; 65(10):e27269.
View in: PubMed

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018 06; 181(6):816-827.
View in: PubMed

Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2344-2353.
View in: PubMed

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
View in: PubMed

Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol. 2018 05 01; 4(5):686-693.
View in: PubMed

Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9.
View in: PubMed

A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018 08; 24(8):1733-1740.
View in: PubMed

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 06 21; 131(25):2836-2845.
View in: PubMed

Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study. Oral Dis. 2018 May; 24(4):580-590.
View in: PubMed

Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival. Cancer Epidemiol Biomarkers Prev. 2018 03; 27(3):345-347.
View in: PubMed

Reply to J.J. Boelens et al. J Clin Oncol. 2018 04 10; 36(11):1176-1177.
View in: PubMed

a1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood. 2018 03 22; 131(12):1372-1379.
View in: PubMed

Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood. 2018 03 08; 131(10):1073-1080.
View in: PubMed

Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018 05; 53(5):535-555.
View in: PubMed

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018 03; 103(3):522-530.
View in: PubMed

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):699-707.
View in: PubMed

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. Blood Adv. 2017 Nov 28; 1(25):2473-2482.
View in: PubMed

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2018 03; 24(3):514-520.
View in: PubMed

Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv. 2017 Nov 14; 1(24):2269-2279.
View in: PubMed

Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood. 2017 12 28; 130(26):2889-2899.
View in: PubMed

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017 Dec 20; 35(36):4003-4011.
View in: PubMed

Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018 02; 24(2):228-241.
View in: PubMed

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017 Sep 10; 35(26):3002-3009.
View in: PubMed

Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep; 124(3):253-260.
View in: PubMed

An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017 Jun 15; 2(12).
View in: PubMed

Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. Blood. 2017 06 15; 129(24):3256-3261.
View in: PubMed

Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017 07 06; 130(1):91-94.
View in: PubMed

Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017 07; 178(1):112-118.
View in: PubMed

Continuation of a Levonorgestrel Intrauterine Device During Hematopoietic Stem Cell Transplant: A Case Report. Anticancer Res. 2017 04; 37(4):1985-1987.
View in: PubMed

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2017 07; 102(7):1185-1191.
View in: PubMed

Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biol Blood Marrow Transplant. 2017 Jun; 23(6):997-1004.
View in: PubMed

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017 04 13; 129(15):2186-2197.
View in: PubMed

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 03 09; 129(10):1380-1388.
View in: PubMed

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
View in: PubMed

Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
View in: PubMed

Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016 11 03; 1(18):e89278.
View in: PubMed

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. Biol Blood Marrow Transplant. 2017 01; 23(1):126-133.
View in: PubMed

Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biol Blood Marrow Transplant. 2017 01; 23(1):113-118.
View in: PubMed

Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016 Dec; 175(5):841-850.
View in: PubMed

An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016 11; 22(11):2084-2091.
View in: PubMed

Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016 10 06; 128(14):1845-1853.
View in: PubMed

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biol Blood Marrow Transplant. 2016 10; 22(10):1808-1815.
View in: PubMed

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
View in: PubMed

Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016 08 18; 128(7):1013-7.
View in: PubMed

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. 2016 10; 101(10):1251-1259.
View in: PubMed

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016 10; 122(19):3005-3014.
View in: PubMed

Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 08; 91(8):793-9.
View in: PubMed

Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 08; 22(8):1504-1510.
View in: PubMed

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1977-9.
View in: PubMed

Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant. 2016 Aug; 51(8):1121-6.
View in: PubMed

Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016 05 19; 127(20):2489-97.
View in: PubMed

An interactive video-based approach to diet education for patients posthematopoietic stem cell transplantation. J Clin Oncol. 2016 Mar; 34(7_suppl):183.
View in: PubMed

Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016 Mar; 91(3):322-9.
View in: PubMed

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65.
View in: PubMed

Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016 Apr; 101(4):499-505.
View in: PubMed

The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016 Apr; 173(1):96-104.
View in: PubMed

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016 May; 22(5):910-8.
View in: PubMed

Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation. F1000Res. 2015; 4:1480.
View in: PubMed

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016 Feb 04; 127(5):646-57.
View in: PubMed

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10; 33(35):4167-75.
View in: PubMed

Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):80-5.
View in: PubMed

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep; 100(9):1222-7.
View in: PubMed

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1907-13.
View in: PubMed

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1583-8.
View in: PubMed

Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94.
View in: PubMed

The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT. J Natl Compr Canc Netw. 2015 Feb; 13(2):184-9.
View in: PubMed

Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant. 2015 May; 21(5):873-80.
View in: PubMed

Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions. Clin Cancer Res. 2015 Mar 01; 21(5):1010-8.
View in: PubMed

Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol. 2015 Feb 01; 33(4):364-9.
View in: PubMed

Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant. 2015 Mar; 21(3):509-16.
View in: PubMed

Readmissions following umbilical cord blood stem cell transplantation. J Clin Oncol. 2014 Oct 20; 32(30_suppl):272.
View in: PubMed

Narrow-band UVB phototherapy for management of oral chronic graft-versus-host disease. Photodermatol Photoimmunol Photomed. 2015 Mar; 31(2):75-82.
View in: PubMed

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Nov; 124(11):4867-76.
View in: PubMed

Outcomes and management strategies for graft failure after umbilical cord blood transplantation. Am J Hematol. 2014 Dec; 89(12):1097-101.
View in: PubMed

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8.
View in: PubMed

Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014 Sep 02; 161(5):319-27.
View in: PubMed

Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec; 89(12):1092-6.
View in: PubMed

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
View in: PubMed

A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1737-43.
View in: PubMed

Characterization of oral involvement in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1717-21.
View in: PubMed

Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1516-21.
View in: PubMed

Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508.
View in: PubMed

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98.
View in: PubMed

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014 Jun 05; 123(23):3664-71.
View in: PubMed

Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant. 2014 Jun; 20(6):858-64.
View in: PubMed

White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol. 2014 Jun; 89(6):591-7.
View in: PubMed

Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014 Apr; 89(4):404-9.
View in: PubMed

Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 May; 20(5):668-75.
View in: PubMed

BK virus disease after allogeneic stem cell transplantation: a cohort analysis. Biol Blood Marrow Transplant. 2014 Apr; 20(4):564-70.
View in: PubMed

Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/ß-catenin pathway and alters immune reconstitution after UCBT. Blood Cancer J. 2014 Jan 17; 4:e178.
View in: PubMed

Isavuconazole treatment of a patient with disseminated mucormycosis. J Clin Microbiol. 2014 Mar; 52(3):1016-9.
View in: PubMed

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014 Feb 27; 123(9):1412-21.
View in: PubMed

Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014 Feb; 20(2):285-7.
View in: PubMed

Readmissions following allogeneic hematopoietic stem cell transplantation. J Clin Oncol. 2013 Nov; 31(31_suppl):265.
View in: PubMed

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014 Mar; 20(3):295-308.
View in: PubMed

Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1713-8.
View in: PubMed

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013 Oct 24; 122(17):3074-81.
View in: PubMed

Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med. 2013 Aug 08; 369(6):517-28.
View in: PubMed

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
View in: PubMed

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013 Aug 22; 122(8):1510-7.
View in: PubMed

Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1374-80.
View in: PubMed

Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center. J Oncol Pract. 2013 Sep; 9(5):e228-33.
View in: PubMed

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 03; 5(179):179ra43.
View in: PubMed

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jun; 19(6):981-7.
View in: PubMed

Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013 Jun 01; 207(11):1694-702.
View in: PubMed

Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013 May; 19(5):804-11.
View in: PubMed

KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. Bone Marrow Transplant. 2013 Jul; 48(7):1000-2.
View in: PubMed

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
View in: PubMed

Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013 Jan; 12(1):123-36.
View in: PubMed

Reducing unnecessary testing on admission in autologous stem cell transplant (SCT) patients. J Clin Oncol. 2012 Dec; 30(34_suppl):185.
View in: PubMed

Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Respir Med. 2013 Feb; 107(2):276-83.
View in: PubMed

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S88-90.
View in: PubMed

Expression of a4ß7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplant. 2013 Apr; 48(4):598-603.
View in: PubMed

Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD. Bone Marrow Transplant. 2013 Apr; 48(4):593-7.
View in: PubMed

Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013 Feb; 27(2):362-9.
View in: PubMed

Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol. 2012 Sep 10; 30(26):3194-201.
View in: PubMed

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012 Sep 10; 30(26):3202-8.
View in: PubMed

Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Ther Adv Hematol. 2012 Aug; 3(4):253-65.
View in: PubMed

Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8.
View in: PubMed

A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 Jul 26; 120(4):905-13.
View in: PubMed

Expression of CD30 in patients with acute graft-versus-host disease. Blood. 2012 Jul 19; 120(3):691-6.
View in: PubMed

Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 2013 Jan; 48(1):146-7.
View in: PubMed

Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1638-48.
View in: PubMed

Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood. 2012 Jun 07; 119(23):5591-8.
View in: PubMed

Does iron overload really matter in stem cell transplantation? Am J Hematol. 2012 Jun; 87(6):569-72.
View in: PubMed

Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
View in: PubMed

To induce, or not to induce, that is the (still unanswered) question. Biol Blood Marrow Transplant. 2012 Mar; 18(3):332-3.
View in: PubMed

Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S111-5.
View in: PubMed

Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant. 2012 Jul; 18(7):989-1006.
View in: PubMed

Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66.
View in: PubMed

Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med. 2011 Nov 23; 3(110):110ra118.
View in: PubMed

Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012 May; 18(5):805-12.
View in: PubMed

Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011 Dec 15; 118(25):6691-7.
View in: PubMed

The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 May; 18(5):708-15.
View in: PubMed

Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011 Nov 03; 118(18):5021-30.
View in: PubMed

Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med. 2011 Sep 01; 365(9):815-24.
View in: PubMed

Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):565-74.
View in: PubMed

Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant. 2012 May; 18(5):690-7.
View in: PubMed

Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation. 2011 Aug 15; 92(3):359-65.
View in: PubMed

Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):575-83.
View in: PubMed

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012 Feb; 18(2):280-8.
View in: PubMed

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1796-803.
View in: PubMed

Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011 Jun; 46(6):884-91.
View in: PubMed

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011 Jun 23; 117(25):6963-70.
View in: PubMed

Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011 Apr; 121(4):1574-84.
View in: PubMed

Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011 Sep; 17(9):1343-51.
View in: PubMed

(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011 Dec; 46(12):1503-9.
View in: PubMed

A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011 Jul; 22(7):1608-1613.
View in: PubMed

Invasive fungal disease after remote inoculation in transplant recipients. Clin Infect Dis. 2011 Jan 01; 52(1):e7-10.
View in: PubMed

Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1196-204.
View in: PubMed

Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60.
View in: PubMed

Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol. 2010 Dec; 85(12):967-71.
View in: PubMed

Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011 Feb 17; 117(7):2275-83.
View in: PubMed

Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Mar; 17(3):434-8.
View in: PubMed

Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):421-8.
View in: PubMed

Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jun; 17(6):852-60.
View in: PubMed

CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant. 2011 May; 17(5):682-92.
View in: PubMed

Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011 May; 46(5):659-67.
View in: PubMed

Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010 Jul; 11(7):653-60.
View in: PubMed

Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res. 2010 May 15; 16(10):2729-39.
View in: PubMed

Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010 May; 120(5):1479-93.
View in: PubMed

Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1180-5.
View in: PubMed

Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1025-31.
View in: PubMed

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1005-17.
View in: PubMed

Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. 2010 Mar 01; 16(5):1642-51.
View in: PubMed

Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant. 2010 Nov; 45(11):1611-7.
View in: PubMed

Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010 Feb 15; 70(4):1344-55.
View in: PubMed

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2010 Apr; 16(4):443-68.
View in: PubMed

Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9.
View in: PubMed

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010 Feb 01; 70(3):906-15.
View in: PubMed

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010 Jun; 16(6):792-800.
View in: PubMed

Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet. 2009 Dec; 41(12):1341-4.
View in: PubMed

Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant. 2010 Jun; 45(6):1062-7.
View in: PubMed

Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant. 2010 May; 45(5):877-85.
View in: PubMed

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010 Feb; 16(2):157-68.
View in: PubMed

Oral chronic graft-versus-host disease scoring using the NIH consensus criteria. Biol Blood Marrow Transplant. 2010 Jan; 16(1):108-14.
View in: PubMed

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009 Oct 29; 114(18):3956-9.
View in: PubMed

Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009 Sep 15; 106(37):15825-30.
View in: PubMed

Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1066-76.
View in: PubMed

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009 Jul; 15(7):844-50.
View in: PubMed

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10; 301(22):2349-61.
View in: PubMed

Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant. 2009 Jul; 15(7):777-84.
View in: PubMed

Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Mar; 15(3):382-8.
View in: PubMed

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009 Apr 16; 113(16):3865-74.
View in: PubMed

High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion. 2009 May; 49(5):995-1002.
View in: PubMed

Finding the right academic job. Hematology Am Soc Hematol Educ Program. 2009; 729-33.
View in: PubMed

Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009 Feb 19; 113(8):1681-8.
View in: PubMed

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74.
View in: PubMed

Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1231-8.
View in: PubMed

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009 Feb 12; 113(7):1581-8.
View in: PubMed

Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008 Oct; 83(10):771-7.
View in: PubMed

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 01; 112(12):4425-31.
View in: PubMed

Donor lymphocyte infusions for acute myeloid leukaemia. Best Pract Res Clin Haematol. 2008 Sep; 21(3):455-66.
View in: PubMed

Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2008 Aug; 14(8):920-6.
View in: PubMed

Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant. 2008 Aug; 42 Suppl 1:S66-S69.
View in: PubMed

Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. J Clin Oncol. 2008 Jul 01; 26(19):3279-81.
View in: PubMed

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25.
View in: PubMed

Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol. 2008 May 01; 26(13):2162-70.
View in: PubMed

Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008 Feb; 14(2):197-207.
View in: PubMed

Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008 Jan; 14(1):110-5.
View in: PubMed

Chronic graft-versus-host disease: how can we release Prometheus? Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):142-50.
View in: PubMed

Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008 Mar; 41(6):523-9.
View in: PubMed

A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1):28-35.
View in: PubMed

High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007 Oct 15; 13(20):6107-14.
View in: PubMed

Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology. 2007 Jul 10; 69(2):156-65.
View in: PubMed

Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007 Aug; 40(3):209-17.
View in: PubMed

Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2007 May; 5(5):474-96.
View in: PubMed

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007 Apr 01; 109(7):3108-14.
View in: PubMed

Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007 Jul 15; 110(2):490-500.
View in: PubMed

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64.
View in: PubMed

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96.
View in: PubMed

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007 May 15; 109(10):4586-8.
View in: PubMed

Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007 Jan; 13(1):82-9.
View in: PubMed

Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood. 2007 Mar 01; 109(5):2001-7.
View in: PubMed

Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64.
View in: PubMed

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55.
View in: PubMed

Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006 Aug; 38(4):305-10.
View in: PubMed

HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 May; 37(9):845-50.
View in: PubMed

IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006 Sep 01; 108(5):1571-9.
View in: PubMed

Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15; 108(2):756-62.
View in: PubMed

Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):732-55.
View in: PubMed

Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res. 2005 Nov 01; 11(21):7692-9.
View in: PubMed

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005 Dec 15; 106(13):4389-96.
View in: PubMed

Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Aug; 11(8):571-5.
View in: PubMed

Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Jul; 11(7):551-7.
View in: PubMed

Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15; 106(8):2903-11.
View in: PubMed

Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res. 2005 Jun 15; 11(12):4504-11.
View in: PubMed

Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005 May; 11(5):383-8.
View in: PubMed

Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Mar; 11(3):213-22.
View in: PubMed

Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005 Feb; 15(1):77-82.
View in: PubMed

Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant. 2005 Jan; 35(1):85-9.
View in: PubMed

Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005 Jan; 35(1):77-83.
View in: PubMed

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 01; 105(7):2973-8.
View in: PubMed

Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol. 2005 Jan; 16(1):151-61.
View in: PubMed

Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant. 2004 Dec; 34(11):987-94.
View in: PubMed

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4.
View in: PubMed

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004 Aug 01; 10(15):5065-71.
View in: PubMed

CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant. 2004 Jul; 34(2):123-8.
View in: PubMed

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004 Sep 01; 104(5):1559-64.
View in: PubMed

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004 May; 10(5):328-36.
View in: PubMed

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 15; 104(4):1224-6.
View in: PubMed

Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004 Apr 19; 199(8):1133-42.
View in: PubMed

Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion. 2004 Feb; 44(2):253-61.
View in: PubMed

Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant. 2003 Dec; 9(12):760-5.
View in: PubMed

Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2003 Dec; 32(12):1145-51.
View in: PubMed

Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003 Nov 01; 102(9):3455-6.
View in: PubMed

Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004 Jan 01; 103(1):353-9.
View in: PubMed

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003 Sep 01; 21(17):3343-50.
View in: PubMed

Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003 Oct 15; 102(8):2768-76.
View in: PubMed

Optimistic expectations and survival after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003 Jun; 9(6):389-96.
View in: PubMed

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82.
View in: PubMed

Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01; 102(5):1601-5.
View in: PubMed

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4712-7.
View in: PubMed

MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 2003 Mar 17; 3:3.
View in: PubMed

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3398-403.
View in: PubMed

Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9.
View in: PubMed

Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002 Oct 15; 100(8):2697-702.
View in: PubMed

CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res. 2002 Oct 01; 62(19):5517-5522.
View in: PubMed

Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood. 2003 Feb 01; 101(3):831-6.
View in: PubMed

A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 2003 Jan 01; 101(1):363-9.
View in: PubMed

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100(13):4337-43.
View in: PubMed

Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood. 2002 Nov 15; 100(10):3479-82.
View in: PubMed

Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 2002 Jul 15; 74(1):49-54.
View in: PubMed

Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res. 2002 Jul; 8(7):2052-60.
View in: PubMed

Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002 Jun 15; 99(12):4610-7.
View in: PubMed

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002 Jun; 117(4):828-34.
View in: PubMed

Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002 Jun; 25(3):283-6.
View in: PubMed

ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24.
View in: PubMed

A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002 Mar; 29(5):373-7.
View in: PubMed

Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002; 8(11):625-32.
View in: PubMed

Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(11):601-7.
View in: PubMed

Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002; 8(8):444-52.
View in: PubMed

Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(3):139-44.
View in: PubMed

The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001 Dec 01; 98(12):3192-204.
View in: PubMed

Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001 Aug 15; 98(4):1116-21.
View in: PubMed

T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001 Aug 15; 98(4):934-9.
View in: PubMed

CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7492-7.
View in: PubMed

A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation. 2001 Apr 27; 71(8):1131-7.
View in: PubMed

CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15; 19(4):1152-9.
View in: PubMed

Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(4):223-9.
View in: PubMed

Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol. 2001 Jan 01; 19(1):242-52.
View in: PubMed

NCCN Practice Guidelines for Chronic Myelogenous Leukemia. Oncology (Williston Park). 2000 Nov; 14(11A):229-40.
View in: PubMed

Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000 Sep; 106(5):705-14.
View in: PubMed

Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45.
View in: PubMed

Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant. 2000 Mar; 25(6):623-32.
View in: PubMed

Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000 Jan 01; 95(1):352-9.
View in: PubMed

Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant. 2000; 6(4):375-86.
View in: PubMed

Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999 Nov 15; 94(10):3325-33.
View in: PubMed

Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35.
View in: PubMed

Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999 Feb; 17(2):561-8.
View in: PubMed

Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999; 5(4):262-8.
View in: PubMed

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998 Oct 27; 95(22):13141-6.
View in: PubMed

Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood. 1998 Oct 15; 92(8):2725-9.
View in: PubMed

Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44.
View in: PubMed

CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998 Jun; 21(12):1177-81.
View in: PubMed

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998 May 15; 91(10):3671-80.
View in: PubMed

IGIV: a potential role for hepatitis B prophylaxis in the bone marrow peritransplant period. Bone Marrow Transplant. 1998 Apr; 21(7):739-42.
View in: PubMed

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998 Jan; 16(1):13-8.
View in: PubMed

Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood. 1997 Dec 15; 90(12):4996-5001.
View in: PubMed

Guillain-Barré syndrome following allogeneic bone marrow transplantation. Neurology. 1997 Dec; 49(6):1711-4.
View in: PubMed

Altered tyrosine phosphorylation via the very late antigen (VLA)/beta1 integrin stimulation is associated with impaired T-cell signaling through VLA-4 after allogeneic bone marrow transplantation. Blood. 1997 Nov 15; 90(10):4222-9.
View in: PubMed

In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Nov; 3(5):267-72.
View in: PubMed

Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest. 1997 Aug 15; 100(4):855-66.
View in: PubMed

CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997 Apr 15; 89(8):3039-47.
View in: PubMed

CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant. 1997 Apr; 3(1):11-7.
View in: PubMed

Donor lymphocyte infusions: the door is open. J Clin Oncol. 1997 Feb; 15(2):416-7.
View in: PubMed

Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. Clin Cancer Res. 1997 Jan; 3(1):17-24.
View in: PubMed

A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther. 1997 Jan 01; 8(1):111-23.
View in: PubMed

Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation. 1996 Nov 15; 62(9):1358-60.
View in: PubMed

High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996 Oct 01; 88(7):2780-6.
View in: PubMed

Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2334-41.
View in: PubMed

Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2228-35.
View in: PubMed

R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. Eur J Immunol. 1996 Sep; 26(9):2149-54.
View in: PubMed

Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1051-6.
View in: PubMed

Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin Cancer Res. 1996 Mar; 2(3):493-9.
View in: PubMed

A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995 Apr 01; 85(7):1881-7.
View in: PubMed

Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma. 1995 Mar; 17(1-2):87-93.
View in: PubMed

Recombinant interleukin-2 infusions and decreased IgG2 subclass concentrations. Blood. 1995 Feb 15; 85(4):925-8.
View in: PubMed

Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood. 1995 Feb 15; 85(4):1132-7.
View in: PubMed

Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. J Clin Apher. 1995; 10(3):139-43.
View in: PubMed

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994 Dec; 12(12):2535-42.
View in: PubMed

Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994 Oct 01; 84(7):2109-14.
View in: PubMed

Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood. 1994 Aug 01; 84(3):964-71.
View in: PubMed

Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation. J Clin Invest. 1994 Aug; 94(2):481-8.
View in: PubMed

The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation. Transplantation. 1994 May 27; 57(10):1465-73.
View in: PubMed

A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. Blood. 1994 May 01; 83(9):2707-14.
View in: PubMed

The effect of minor ABO mismatches on the incidence of graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 1994 Mar 15; 57(5):780.
View in: PubMed

Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood. 1993 Nov 01; 82(9):2790-6.
View in: PubMed

Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood. 1993 Oct 15; 82(8):2568-76.
View in: PubMed

Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Blood. 1993 Oct 01; 82(7):2216-23.
View in: PubMed

Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant. 1993 Sep; 12(3):243-51.
View in: PubMed

Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993 Aug 15; 82(4):1366-76.
View in: PubMed

Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol. 1993 May; 11(5):931-6.
View in: PubMed

Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. Bone Marrow Transplant. 1993; 12 Suppl 3:S7-10.
View in: PubMed

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest. 1993 Jan; 91(1):123-32.
View in: PubMed

Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992 Jul; 10(7):1191-200.
View in: PubMed

Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood. 1992 May 01; 79(9):2229-36.
View in: PubMed

Immune-mediated cytopenia following bone marrow transplantation. Case reports and review of the literature. Medicine (Baltimore). 1992 Mar; 71(2):73-83.
View in: PubMed

Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. 1992 Mar 01; 175(3):779-88.
View in: PubMed

Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 1992 Jan 15; 79(2):517-26.
View in: PubMed

Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991 Dec; 52(6):1014-9.
View in: PubMed

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol. 1991 Dec; 9(12):2110-9.
View in: PubMed

Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood. 1991 Nov 15; 78(10):2759-67.
View in: PubMed

Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant. 1991 Aug; 8(2):143-5.
View in: PubMed

Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood. 1991 Jun 01; 77(11):2524-9.
View in: PubMed

Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood. 1991 Apr 15; 77(8):1837-44.
View in: PubMed

Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood. 1991 Feb 15; 77(4):712-20.
View in: PubMed

Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant. 1991 Jan; 7(1):23-33.
View in: PubMed

Autoimmune pancytopenia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990 Dec; 6(6):445-7.
View in: PubMed

Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant. 1990 Nov; 6(5):329-31.
View in: PubMed

T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood. 1990 Jul 01; 76(1):235-44.
View in: PubMed

Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood. 1990 May 15; 75(10):2076-84.
View in: PubMed

Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol. 1990 May; 8(5):784-91.
View in: PubMed

High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent. Cancer. 1989 Nov 15; 64(10):2014-8.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top